{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:04:24Z","timestamp":1791389064281,"version":"4.3.3"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Asthma is the most common diagnosis in military personnel who endorse chronic dyspnea. Service members have unique occupational risk factors, and there is concern that airborne exposures in the deployed environment as well as other occupational exposures may contribute to the development of asthma or exacerbate pre-existing disease. Asthma phenotyping with clinical biomarkers such as serum immunoglobulin E (IgE) levels and eosinophil (EOS) counts is useful in defining treatment strategies for the management of asthma. This study sought to characterize the phenotype of medically separated military personnel with career-limiting asthma to define potential management strategies and guide future research evaluating the unexplained prevalence of asthma in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A retrospective chart review of active duty service members (ADSM) who underwent fitness for duty evaluation via medical evaluation board between 2005 and 2016 and were separated with a minimum 30% conditional disability rating for asthma was performed. Only ADSM who were diagnosed with asthma by a pulmonologist and had spirometry data available were included in the analysis. Demographics, spirometry data, and laboratory data to include IgE levels, radioallergosorbent panels, and EOS counts were analyzed from the DoD electronic medical record.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 141 service members were evaluated with a mean age of 42\u2009\u00b1\u20096.8\u2009years, mean serum EOS count of 300\u2009\u00b1\u2009358 cells\/\u03bcL, and mean IgE level of 305\u2009\u00b1\u2009363 IU\/mL. The patients were further categorized into 4 subgroups based on serum EOS count and IgE level: group A with IgE\u2009&amp;lt;\u2009100 IU\/mL and EOS\u2009&amp;lt;\u2009300 cells\/\u03bcL (n\u2009=\u200945; 33%), group B with IgE\u2009&amp;gt;\u2009100 IU\/mL and EOS\u2009&amp;lt;\u2009300 cells\/\u03bcL (n\u2009=\u200944; 32%), group C with IgE\u2009&amp;lt;\u2009100 IU\/mL and EOS\u2009&amp;gt;\u2009300 cells\/\u03bcL (n\u2009=\u20096; 1%), and group D with IgE\u2009&amp;gt;\u2009100 IU\/mL, EOS\u2009&amp;gt;\u2009300 cells\/\u03bcL (n\u2009=\u200946; 34%). Among the cohorts, there were no statistically significant differences in demographics, body mass index, spirometry, smoking history, or disability rating.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The majority of ADSM with a defined asthma history do not have concordant elevations in serum IgE and blood EOS suggestive of a Th2-high phenotype. Asthma in this population is heterogeneous, and phenotyping using clinical biomarkers may be useful to define optimal treatment strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usae060","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T16:13:18Z","timestamp":1724083998000},"page":"137-141","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing the Asthma Phenotype of Military Personnel"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-5811","authenticated-orcid":false,"given":"Joshua M","family":"Boster","sequence":"first","affiliation":[{"name":"Department of Medicine, Pulmonary\/Critical Service, Brooke Army Medical Center , JBSA Fort Sam Houston, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Moore III","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pulmonary\/Critical Service, Brooke Army Medical Center , JBSA Fort Sam Houston, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T","family":"Stoffel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pulmonary\/Critical Service, Brooke Army Medical Center , JBSA Fort Sam Houston, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S","family":"Barber","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pulmonary\/Critical Service, Brooke Army Medical Center , JBSA Fort Sam Houston, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo C","family":"Houle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pulmonary\/Critical Service, Brooke Army Medical Center , JBSA Fort Sam Houston, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pulmonary\/Critical Service, Brooke Army Medical Center , JBSA Fort Sam Houston, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pulmonary\/Critical Service, Brooke Army Medical Center , JBSA Fort Sam Houston, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"2024082004061231900_R1","article-title":"Asthma data, statistics, and surveillance","author":"Centers for Disease Control and Prevention","year":"2023"},{"issue":"Suppl 10","key":"2024082004061231900_R2","first-page":"6S","article-title":"Management of asthma in the military","volume":"32","author":"Rawlins","year":"2015","journal-title":"Fed Pract"},{"issue":"1","key":"2024082004061231900_R3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1081-1206(10)60857-5","article-title":"Asthma hospitalizations among US military personnel, 1994 to 2004","volume":"98","author":"Hansen","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"2024082004061231900_R4","first-page":"239","article-title":"Underdiagnosis of asthma in young adults presenting for USAF basic training","volume":"69","author":"Nish","year":"1992","journal-title":"Ann Allergy"},{"key":"2024082004061231900_R5","first-page":"173","article-title":"Deployment-related respiratory issues","author":"Morris","year":"2016","journal-title":"U S Army Med Depart J"},{"issue":"4","key":"2024082004061231900_R6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/08958370802672891","article-title":"Potential health implications associated with particulate matter exposure in deployed settings in Southwest Asia","volume":"21","author":"Weese","year":"2009","journal-title":"Inhal Toxicol"},{"issue":"12","key":"2024082004061231900_R7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.7205\/MILMED.172.12.1264","article-title":"The prevalence and impact of respiratory symptoms in asthmatics and non-asthmatics during deployment","volume":"172","author":"Roop","year":"2007","journal-title":"Mil Med"},{"issue":"1","key":"2024082004061231900_R8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1055\/s-0037-1606218","article-title":"Biologic therapy and asthma","volume":"39","author":"Viswanathan","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"issue":"7","key":"2024082004061231900_R9","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/j.jaip.2021.02.059","article-title":"Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry","volume":"9","author":"Denton","year":"2021","journal-title":"J Allergy Coin Immunol Pract"},{"issue":"10","key":"2024082004061231900_R10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/CM9.0000000000001990","article-title":"Characteristics, phenotypes, mechanisms and management of severe asthma","volume":"135","author":"Chung","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"2024082004061231900_R11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5409\/wjcp.v4.i2.13","article-title":"Clinical asthma phenotyping: a trial for bridging gaps in asthma management","volume":"4","author":"Sedan","year":"2015","journal-title":"World J Clin Pediatr"},{"issue":"3","key":"2024082004061231900_R12","doi-asserted-by":"publisher","first-page":"00013","DOI":"10.1183\/23120541.00013-2018","article-title":"Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration","volume":"4","author":"Pembrey","year":"2018","journal-title":"ERJ Open Res"},{"issue":"2","key":"2024082004061231900_R13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2024082004061231900_R14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jaip.2019.11.006","article-title":"T2-\u201clow\u201d asthma: overview and management strategies","volume":"8","author":"Fitzpatrick","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2024082004061231900_R15","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10698","article-title":"Biological therapies targeting the type 2 inflammatory pathway in severe asthma","volume":"22","author":"Fildan","year":"2021","journal-title":"Exp Ther Med"},{"key":"2024082004061231900_R16","article-title":"Global strategy for asthma management and prevention","author":"Global Initiative for Asthma (GINA)"},{"key":"2024082004061231900_R17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.983852","article-title":"Monoclonal antibodies in the management of asthma: dead ends, current status and future perspectives","volume":"13","author":"Kardas","year":"2022","journal-title":"Front Immunol"},{"key":"2024082004061231900_R18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.rmed.2019.10.003","article-title":"Refractory asthma phenotyping based on immunoglobulin E levels and eosinophilic counts: A real life study","volume":"158","author":"Lababidi","year":"2019","journal-title":"Respir Med"},{"issue":"1","key":"2024082004061231900_R19","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-014-0144-8","article-title":"Longitudinal increase in total IgE levels in patients with adult asthma: an association with poor asthma control","volume":"15","author":"Tanaka","year":"2014","journal-title":"Respir Res"},{"key":"2024082004061231900_R20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.rmed.2018.10.025","article-title":"Eosinophilic asthma, according to a blood eosinophil criterion, is associated with disease severity and lack of control among underprivileged urban Brazilians","volume":"145","author":"Lima-Matos","year":"2018","journal-title":"Respir Med"},{"key":"2024082004061231900_R21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.rmed.2017.12.001","article-title":"A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels","volume":"134","author":"Haughney","year":"2018","journal-title":"Respir Med"},{"issue":"5","key":"2024082004061231900_R22","first-page":"568","article-title":"Clinical asthma syndromes and important asthma mimics","volume":"53","author":"King","year":"2008","journal-title":"Respir Care"},{"issue":"3","key":"2024082004061231900_R23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.01.057","article-title":"Mechanisms of occupational asthma","volume":"123","author":"Maestrelli","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2024082004061231900_R24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/all.13542","article-title":"Are high- and low-molecular-weight sensitizing agents associated with different clinical phenotypes of occupational asthma?","volume":"74","author":"Vandenplas","year":"2019","journal-title":"Allergy"},{"issue":"6","key":"2024082004061231900_R25","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.chest.2020.01.024","article-title":"Clinical evaluation of deployed military personnel with chronic respiratory symptoms: Study of Active Duty Military for Pulmonary Disease Related to Environmental Deployment Exposures (STAMPEDE) III","volume":"157","author":"Morris","year":"2020","journal-title":"Chest"},{"issue":"4","key":"2024082004061231900_R26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/02770903.2014.973502","article-title":"The impact of combat deployment on asthma diagnosis and severity","volume":"52","author":"DelVecchio","year":"2015","journal-title":"J Asthma"},{"key":"2024082004061231900_R27","volume-title":"Long-term Health Consequences of Exposure to Burn Pits in Iraq and Afghanistan","author":"IOM (Institute of Medicine)","year":"2011"},{"issue":"4","key":"2024082004061231900_R28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.anai.2018.07.033","article-title":"Selecting the right biologic for your patients with severe asthma","volume":"121","author":"Manka","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"2024082004061231900_R29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.anai.2020.04.031","article-title":"How to compare the efficacy of biologic agents in asthma","volume":"125","author":"Viswanathan","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"2024082004061231900_R30","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2024082004061231900_R31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"2024082004061231900_R32","article-title":"Prescribing information: TEZSPIRE (tezepelumab)","author":"US Food and Drug Administration"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/189\/Supplement_3\/137\/58855452\/usae060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/189\/Supplement_3\/137\/58855452\/usae060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:06:28Z","timestamp":1724126788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/189\/Supplement_3\/137\/7735939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":32,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2024,8,19]]},"published-print":{"date-parts":[[2024,8,19]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usae060","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,19]]}}}